U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 billion
(Reuters) -The United States has signed contracts worth about $1 billion for doses of the antibody-based COVID-19 treatment from Britain’s GSK and U.S.-based Vir Biotechnology, […]
Read more